Pulmonary artery hypertension (PAH) is a combination of factors caused abnormal pulmonary hemodynamics. Pulmonary vascular resistance (PVR) progressive as clinical features of PAH.
肺动脉高压(PAH)是多种因素引起的肺血流动力学异常，以肺血管阻力进行性升高为临床特征的一组疾病。
OBJECTIVE: To study pharmacological mechanism of bosentan for treatment of pulmonary artery hypertension (PAH) and evaluate its clinical efficacy and the safety.
目的：探讨波生坦治疗肺动脉高压的药理机制，并评价其临床疗效和用药安全性。
Objective: Our aim was to study the levels of atrial natriuretic peptide (ANP) and pulmonary perfusion imaging in determining of pulmonary artery hypertension (PAH).
目的：探讨血浆心钠素含量和肺灌注显像判定肺动脉高压的程度及其意义。
Objective To evaluate MRI in assessing the normality and compliance of pulmonary artery, and in determining the causes of pulmonary artery hypertension (PAH).
目的确定MRI评价正常肺动脉和肺动脉高压(pah)病因及其顺应性变化的价值。
Pulmonary arterial hypertension(PAH) is a set of rare and prognosis of disease. The disease to heighten the pulmonary artery pressure and resistance as feature.
肺动脉高压（PAH）是一组少见的、预后不良的疾病，以增高的肺动脉压力和阻力为特征。
Pulmonary arterial hypertension(PAH) is a set of rare and prognosis of disease. The disease to heighten the pulmonary artery pressure and resistance as feature.
肺动脉高压（PAH）是一组少见的、预后不良的疾病，以增高的肺动脉压力和阻力为特征。
应用推荐